Athanasios Pseftogas
Thessaloniki, ESYE12, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Guanidine-based azines from N-heterocyclic carbene (NHC)-derived selenoureas and diazo compounds: synthesis, structural diversification, and biological evaluation.
Journal: Organic & biomolecular chemistry
Published: June 16, 2026
The deubiquitinase activity of CYLD is required for B cell differentiation.
Journal: Cell death & disease
Published: August 07, 2025
Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
Journal: Anticancer research
Published: February 25, 2024
Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency.
Journal: Cancers
Published: October 01, 2023
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
Journal: Leukemia
Published: July 04, 2023
The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.
Journal: Cancers
Published: May 27, 2020
HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.
Journal: OncoTargets and therapy
Published: February 17, 2020
Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
Journal: The international journal of biochemistry & cell biology
Published: August 02, 2016
Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: March 13, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026